Omega-3 fails to make the grade for early COVID-19 therapy
Researchers report results from a trial in 2000 Argentinian patients with early disease
A trial of high-dose icosapent ethyl for early COVID-19 has failed to show a benefit, although there was a trend to better outcomes with the substance, researchers report.
The omega-3 compound — a prescription oral form of eicosapentaenoic acid — was trialled in 2052 Argentinian patients aged 40 or over who had tested positive for COVID-19 with no current need for hospitalisation.
All had experienced symptoms of the infection — fever, cough, sore throat, shortness of breath or muscle aches —
